+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Use of a Qualification Phantom for PET Brain Imaging in a Multicenter Consortium: A Collaboration Between the Pediatric Brain Tumor Consortium and the SNMMI Clinical Trials Network



Use of a Qualification Phantom for PET Brain Imaging in a Multicenter Consortium: A Collaboration Between the Pediatric Brain Tumor Consortium and the SNMMI Clinical Trials Network



Journal of Nuclear Medicine 2018



The purpose of this study was to assess image quality and quantitative brain PET across a multi-center consortium. Methods: All academic centers and children's hospitals in the Pediatric Brain Tumor Consortium (PBTC) scanned a phantom developed by the Society of Nuclear Medicine and Molecular Imaging Clinical Trials Network (SNMMI CTN) for the validation of brain PET studies associated with clinical trials. The phantom comprises 2 separate, fillable sections: a resolution/uniformity section and a clinical simulation section. The resolution/uniformity section is a cylinder 12.7 cm long, 20 cm diameter; spatial resolution is evaluated subjectively with 2 sets of rods ("hot" and "cold") of varying diameter (4.0, 5.0, 6.25, 7.81, 9.67 and 12.2 mm) and spacing (twice the rod diameter). The clinical simulation section simulates a transverse section of midbrain with ventricles, gray and white matter compartments. If properly filled, hot rods have an 4:1 target-to-background ratio and gray to white matter sections have a 4:1 ratio. Uniformity and image quality were evaluated using the standardized uptake value (SUV) in a small volume of interest as well as subjectively by 2 independent observers using a 4-point scale. Results: Eleven PBTC sites scanned the phantom on 13 PET scanners. The phantom's complexity led to suboptimal filling, particularly of the hot rod section, in 5 sites. The SUV in the uniformity section was within 10% of unity on only 5 of 13 scanners, although 12 of 13 were subjectively judged to have very good to excellent uniformity. Four of 6 hot rods were discernable by all 13 scanners while 3 of 6 cold rods were discernable by only 5 scanners. Four of 13 scanners had a gray/white matter ratio between 3.0 and 5.0 (4.0 is truth); however, 11 of 13 scanners were subjectively judged to have very good or excellent image quality. Conclusion: Eleven sites were able to image a powerful phantom developed by the SNMMI CTN that evaluated image uniformity, spatial resolution and image quality of brain PET. There was considerable variation in PET data across the PBTC sites possibly resulting from variations in scanning across the sites due to challenges in filling the phantom.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065990382

Download citation: RISBibTeXText

PMID: 30530829

DOI: 10.2967/jnumed.118.219998


Related references

Tmod-20. The Pediatric Brain Tumor Atlas: An Initiative By The ChildrenS Brain Tumor Tissue Consortium And Pacific Pediatric Neurooncology Consortium. Neuro-Oncology 21(Suppl._2): ii125, 2019

18F-FDG PET and MR imaging associations across a spectrum of pediatric brain tumors: a report from the pediatric brain tumor consortium. Journal of Nuclear Medicine 55(9): 1473-1480, 2014

MRI as a central component of clinical trials analysis in brainstem glioma: a report from the Pediatric Brain Tumor Consortium (PBTC). Neuro-Oncology 13(4): 417-427, 2011

Ept-06Outcomes For Patients With Recurrent Medulloblastoma Or Ependymoma Enrolled On Phase Ii Clinical Trials: An Analysis Of Contemporary Children'S Oncology Group (Cog) And Pediatric Brain Tumor Consortium (Pbtc) Trials. Neuro-Oncology 18(Suppl 3): iii25.1-iii25, 2016

Access to Children's Oncology Group and Pediatric Brain Tumor Consortium phase 1 clinical trials: Racial/ethnic dissimilarities in participation. Cancer 122(20): 3207-3214, 2016

Pediatric brain tumor consortium multisite assessment of apparent diffusion coefficient z-axis variation assessed with an ice-water phantom. Academic Radiology 22(3): 363-369, 2015

Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. Journal of Clinical Oncology 26(6): 919-924, 2008

Continual reassessment method vs. traditional empirically based design: modifications motivated by Phase I trials in pediatric oncology by the Pediatric Brain Tumor Consortium. Journal of Biopharmaceutical Statistics 19(3): 437-455, 2009

Evaluation of 18F-FDG PET and MRI associations in pediatric diffuse intrinsic brain stem glioma: a report from the Pediatric Brain Tumor Consortium. Journal of Nuclear Medicine 52(2): 188-195, 2011

Exploratory evaluation of MR permeability with 18F-FDG PET mapping in pediatric brain tumors: a report from the Pediatric Brain Tumor Consortium. Journal of Nuclear Medicine 54(8): 1237-1243, 2013

Advancing brain tumor epidemiology - multi-level integration and international collaboration: The 2018 Brain Tumor Epidemiology Consortium meeting report. Clinical Neuropathology 37(6): 254-261, 2018

Phase I trial of VNP40101M (Cloretazine) in children with recurrent brain tumors: a pediatric brain tumor consortium study. Clinical Cancer Research 14(4): 1124-1130, 2008

The neuroimaging center of the Pediatric Brain Tumor Consortium - Collaborative neuroimaging in pediatric brain tumor research: A work in progress. AJNR 28(4): 603-607, 2007

Predictors of adaptive functioning and psychosocial adjustment in children with pediatric brain tumor: a report from the Brain Radiation Investigative Study Consortium. Pediatric Blood & Cancer 62(3): 509-516, 2015

Predicting changes in adaptive functioning and behavioral adjustment following treatment for a pediatric brain tumor: A report from the Brain Radiation Investigative Study Consortium. Psycho-Oncology, 2017